Morgan Stanley analyst Maxwell Skor has maintained their neutral stance on INSM stock, giving a Hold rating on August 20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Maxwell Skor has given his Hold rating due to a combination of factors related to the recent developments in Insmed’s clinical trials and market potential. The TETON-2 study by United Therapeutics, which Insmed is closely monitoring, showed promising results in treating idiopathic pulmonary fibrosis (IPF) with Tyvaso, meeting its primary endpoint and demonstrating significant improvements in forced vital capacity.
Despite these positive outcomes, the decision to rate Insmed as Hold reflects the anticipation of further clarity on Insmed’s plans to advance their TPIP into similar indications, as well as upcoming regulatory discussions. The Hold rating suggests a cautious approach, awaiting additional data and strategic decisions that could influence Insmed’s future growth and market positioning.
Skor covers the Healthcare sector, focusing on stocks such as Pharvaris, Insmed, and Ascendis Pharma. According to TipRanks, Skor has an average return of 8.2% and a 62.96% success rate on recommended stocks.
In another report released on August 20, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $135.00 price target.